MA41790A - Dérivé de morphinane - Google Patents

Dérivé de morphinane

Info

Publication number
MA41790A
MA41790A MA041790A MA41790A MA41790A MA 41790 A MA41790 A MA 41790A MA 041790 A MA041790 A MA 041790A MA 41790 A MA41790 A MA 41790A MA 41790 A MA41790 A MA 41790A
Authority
MA
Morocco
Prior art keywords
morphinane derivative
morphinane
derivative
Prior art date
Application number
MA041790A
Other languages
English (en)
Other versions
MA41790B1 (fr
Inventor
Hideaki Fujii
Kohei Hayashida
Masaaki Hirose
Hiroshi Nagase
Eriko Nakata
Isao Ooi
Akiyoshi Saitoh
Original Assignee
Nippon Chemiphar Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56919074&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA41790(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nippon Chemiphar Co filed Critical Nippon Chemiphar Co
Publication of MA41790A publication Critical patent/MA41790A/fr
Publication of MA41790B1 publication Critical patent/MA41790B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
MA41790A 2015-03-17 2016-03-17 Dérivé de morphinane MA41790B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2015054079 2015-03-17
PCT/JP2016/058475 WO2016148232A1 (fr) 2015-03-17 2016-03-17 Dérivé de morphinane

Publications (2)

Publication Number Publication Date
MA41790A true MA41790A (fr) 2021-06-02
MA41790B1 MA41790B1 (fr) 2022-02-28

Family

ID=56919074

Family Applications (1)

Application Number Title Priority Date Filing Date
MA41790A MA41790B1 (fr) 2015-03-17 2016-03-17 Dérivé de morphinane

Country Status (24)

Country Link
US (4) US10442802B2 (fr)
EP (2) EP3974430A1 (fr)
JP (4) JP6692345B2 (fr)
KR (2) KR20230104767A (fr)
CN (3) CN107614500B (fr)
AU (2) AU2016234222C1 (fr)
BR (1) BR112017019805B1 (fr)
CA (1) CA2979023C (fr)
CY (1) CY1124908T1 (fr)
DK (1) DK3272750T3 (fr)
ES (1) ES2904511T3 (fr)
HK (1) HK1249900A1 (fr)
HU (1) HUE057266T2 (fr)
IL (1) IL254473B (fr)
MA (1) MA41790B1 (fr)
MX (2) MX2021008741A (fr)
MY (1) MY197742A (fr)
PH (1) PH12017501655A1 (fr)
PL (1) PL3272750T3 (fr)
RU (1) RU2762567C2 (fr)
SG (2) SG11201707427TA (fr)
TW (2) TWI775723B (fr)
WO (1) WO2016148232A1 (fr)
ZA (1) ZA201706882B (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018030382A1 (fr) 2016-08-09 2018-02-15 国立大学法人 筑波大学 Dérivé de morphinane
EP3513792B9 (fr) * 2016-09-16 2024-07-10 Nippon Chemiphar Co., Ltd. Dérivés de morphinane pour le traitement de maladies associées à un agoniste des recepteurs opioïdes delta
JP7283711B2 (ja) * 2016-10-03 2023-05-30 学校法人星薬科大学 モルヒナン誘導体を含む医薬組成物及びその鎮痛剤への使用
CA3146790A1 (fr) 2019-07-19 2021-01-28 Nippon Chemiphar Co., Ltd. Procede de production d'un derive de morphinane
KR20220035378A (ko) 2019-07-19 2022-03-22 닛뽕 케미파 가부시키가이샤 페놀 유도체의 제조 방법
EP4206203A1 (fr) 2020-08-28 2023-07-05 Nippon Chemiphar Co., Ltd. Procédé de préparation d'un dérivé de morphinane à chaîne principale formée d'éther diarylique utilisant un nouveau catalyseur au cuivre

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005231995A (ja) 1999-12-22 2005-09-02 Meiji Seika Kaisha Ltd オピオイドδ受容体アゴニスト／アンタゴニストとして有用なスピロ化合物
DE10161963A1 (de) 2001-12-17 2003-07-03 Johannes Schuetz 6-Aminomorphinanderivate, Herstellungsverfahren dafür und deren Verwendung
CL2004000754A1 (es) 2003-04-11 2005-02-25 Janssen Pharmaceutica Nv Uso de compuestos derivados de 4-fenil-4-(1h-imidazol-2-il)piperidina, como agonistas delta-opioides no peptidicos, para preparar un medicamento util en prevenir o tratar trastornos del sistema nervioso central.
WO2006107254A1 (fr) 2005-04-04 2006-10-12 Astrazeneca Ab Nouveaux diazaspiroalcanes et leur application au traitement de maladies faisant intervenir ccr8
WO2008001859A1 (fr) 2006-06-30 2008-01-03 School Juridical Person Kitasato Gakuen AGONISTE DES RÉCEPTEURS δ DES OPIOÏDES
CN101918403A (zh) 2007-09-06 2010-12-15 阵列生物制药公司 作为酪氨酸激酶抑制剂的吡唑并吡啶类化合物
EP2493878B1 (fr) 2009-10-30 2016-10-12 Janssen Pharmaceutica NV Pyrazines en tant que modulateurs du récepteur opioïde delta
WO2011090935A1 (fr) 2010-01-19 2011-07-28 Merck Sharp & Dohme Corp. Composés pyrazolo[1,5-a]pyrimidines en tant qu'inhibiteurs de mtor
US8987293B2 (en) 2010-12-23 2015-03-24 Phoenix Pharmalabs, Inc. Morphinans useful as analgesics
JP2014073964A (ja) 2011-01-28 2014-04-24 Kitasato Institute モルヒナン誘導体
WO2013035833A1 (fr) 2011-09-09 2013-03-14 学校法人北里研究所 Dérivé de morphinane
WO2014021273A1 (fr) * 2012-07-30 2014-02-06 学校法人北里研究所 Dérivés morphinane
ES2623262T3 (es) 2012-12-14 2017-07-10 Purdue Pharma Lp Derivados de morfinano que contienen nitrógeno y el uso de los mismos
JP6173431B2 (ja) * 2013-03-08 2017-08-02 学校法人北里研究所 モルヒナン誘導体
EP3513792B9 (fr) 2016-09-16 2024-07-10 Nippon Chemiphar Co., Ltd. Dérivés de morphinane pour le traitement de maladies associées à un agoniste des recepteurs opioïdes delta

Also Published As

Publication number Publication date
TWI778933B (zh) 2022-09-21
WO2016148232A1 (fr) 2016-09-22
TW202244044A (zh) 2022-11-16
PH12017501655B1 (en) 2018-03-12
US11643411B2 (en) 2023-05-09
CA2979023A1 (fr) 2016-09-22
US10995092B2 (en) 2021-05-04
CA2979023C (fr) 2023-09-26
CN107614500A (zh) 2018-01-19
AU2020270503A1 (en) 2020-12-17
AU2020270503C1 (en) 2023-08-10
EP3272750A4 (fr) 2018-08-08
MY197742A (en) 2023-07-12
US20230159530A1 (en) 2023-05-25
US20200079775A1 (en) 2020-03-12
AU2020270503B2 (en) 2023-02-02
JP2020117533A (ja) 2020-08-06
CY1124908T1 (el) 2023-01-05
MX2017011824A (es) 2018-04-20
US20180057493A1 (en) 2018-03-01
HK1249900A1 (zh) 2018-11-16
US10442802B2 (en) 2019-10-15
RU2762567C2 (ru) 2021-12-21
BR112017019805B1 (pt) 2023-01-31
CN113292559A (zh) 2021-08-24
IL254473B (en) 2022-05-01
JP6692345B2 (ja) 2020-05-13
KR20230104767A (ko) 2023-07-10
AU2016234222A1 (en) 2017-10-26
CN113292558A (zh) 2021-08-24
TWI775723B (zh) 2022-09-01
EP3272750B1 (fr) 2021-11-03
ES2904511T3 (es) 2022-04-05
PH12017501655A1 (en) 2018-03-12
DK3272750T3 (en) 2022-01-03
SG10201907667RA (en) 2019-09-27
MA41790B1 (fr) 2022-02-28
AU2016234222B2 (en) 2020-08-27
AU2016234222C1 (en) 2021-02-11
EP3272750A1 (fr) 2018-01-24
CN113292559B (zh) 2024-04-02
JP2022081656A (ja) 2022-05-31
ZA201706882B (en) 2022-02-23
US20210040094A1 (en) 2021-02-11
CN107614500B (zh) 2021-06-15
IL254473A0 (en) 2017-11-30
BR112017019805A2 (pt) 2018-05-29
PL3272750T3 (pl) 2022-03-07
RU2017134286A3 (fr) 2019-04-19
RU2017134286A (ru) 2019-04-05
TW201638089A (zh) 2016-11-01
KR20180002616A (ko) 2018-01-08
AU2020270503C9 (en) 2024-02-29
KR102551969B1 (ko) 2023-07-05
MX2021008741A (es) 2022-11-01
JP7375076B2 (ja) 2023-11-07
EP3974430A1 (fr) 2022-03-30
HUE057266T2 (hu) 2022-05-28
AU2020270503B9 (en) 2023-10-12
SG11201707427TA (en) 2017-10-30
JPWO2016148232A1 (ja) 2018-03-08
JP2024010098A (ja) 2024-01-23

Similar Documents

Publication Publication Date Title
DK3283625T3 (da) Nukleasemedieret genomeditering
DK3319956T3 (da) Substituerede oxopyridinderivater
DK3331869T3 (da) Muscarinagonister
DK3305788T3 (da) Janus-kinase-hæmmer
DK3331528T3 (da) Muskarinagonister
DK3277719T3 (da) Polypeptider
DK3360890T3 (da) Genterapi
DK3331529T3 (da) Muskarinagonister
DK3310450T3 (da) Olie-vand-separator
DK3270930T3 (da) Præeklampsi
CL2016002165A1 (es) Compuestos de aminocarbonilcarbamato
MA41790A (fr) Dérivé de morphinane
DK3394281T3 (da) Gærcelle
DK3292136T3 (da) Penicillin-g-acylaser
DK3597189T3 (da) Krystallinske forbindelser
DK3274482T3 (da) Stenborsknop
DE112015006486A5 (de) Inkubationsrinne
DK3318308T3 (da) Badmintonketsjer
DE112016005599A5 (de) Strahlungsgrill
DE112015005906A5 (de) Gurtschlossbringer
ES1140083Y (es) Descompatactador tetrafunción
DE102015206660A8 (de) Plattenaufteilanlage
MA41641A (fr) Dérivés de tétrahydropyranylbenzamide
HK1259107A1 (zh) 氨基唑衍生物
DE112016001124A5 (de) Spannschutz